70 results
8-K
EX-99.1
ITCI
Intra-Cellular Therapies Inc
7 May 24
Intra-cellular Therapies Reports First Quarter 2024 Financial Results
7:40am
of ITI-1020.
ITI-333 program: ITI-333, a 5-HT2A receptor antagonist and m-opioid receptor partial agonist, provides potential utility in the treatment … of opioid use disorder and pain. A multiple ascending dose study and a positron emission tomography (PET) study are both ongoing.
ITI-1500 Non
424B5
ITCI
Intra-Cellular Therapies Inc
18 Apr 24
Prospectus supplement for primary offering
5:23pm
to develop new drugs to treat opioid addiction and safe, effective, non-addictive treatments to manage pain. ITI-333 is a novel compound that uniquely … combines activity as an antagonist at serotonin 5-HT2A receptors and a partial agonist at µ-opioid receptors. These combined actions support the potential
8-K
EX-99.2
ITCI
Intra-Cellular Therapies Inc
16 Apr 24
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:40pm
. There is a pressing need to develop new drugs to treat opioid addiction and safe, effective, non-addictive treatments to manage pain. ITI-333 is a novel … compound that uniquely combines activity as an antagonist at serotonin 5-HT2A receptors and a partial agonist at µ-opioid receptors. These combined actions
424B5
3bi5zy hftpmn1fe
16 Apr 24
Prospectus supplement for primary offering
4:37pm
S-3ASR
nmxqyo
16 Apr 24
Automatic shelf registration
4:01pm
8-K
EX-99.1
ra5qdwws
22 Feb 24
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Corporate Update
7:39am
8-K
EX-99.1
8nkoz44h1 p7i4mciv
2 Nov 23
Intra-cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
8:01am
8-K
EX-99.1
kxc8 bxzb4beha4wi
3 Aug 23
Intra-cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
7:39am
8-K
EX-99.1
on4b uiol
4 May 23
Intra-cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
x6drl6xorxj e4jrr
9 Aug 22
Intra-cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7:38am